about us

soloMER® technology


licensing opportunities

our mission

To deliver and commercialise effective therapeutics for improved patient treatment of autoimmune diseases and cancer.

our vision

To improve the outcomes and quality of life for people combating disease now, and in the future.

our values

Development of therapeutics for patient benefit.     Strong science to deliver effective therapeutics.

Individual challenge for collective success.      Strength through diversity.

leading the way with soloMER® technology

soloMERs® are Elasmogen’s proprietary biologics platform delivering a pipeline of disease targeting domains with differentiated binding interactions resulting in new mechanisms of action. Their simple architecture enables rapid reformatting to generate effective multi-functional therapeutic products.



license our patented inventions and proprietary products

Elasmogen has succeeded in isolating high affinity, highly selective and differentiated, patent protected soloMERs® against a number of different target classes demonstrating the power of our platforms. We are actively looking for potential partners who would like to license our products and/or gain access to our proprietary technology platforms for de novo selection campaigns.




First in Class Bispecific Next Generation ADC targeting EGFR/ROR1 to progress into pre-clinical development

Jun 4, 2024 | News

Almac Discovery, a research driven drug discovery company and member of the Almac Group, has announced the nomination of a new pre-clinical candidate molecule...

2024 Impact Report: The Scottish National Investment Bank helps Elasmogen to develop next-generation therapeutic drugs

Apr 7, 2024 | News

https://www.youtube.com/watch?v=YpcwHA7GG0w Hear from Elasmogen's CEO, Prof. Caroline Barelle, how The Scottish National Investment Bank helps to develop...

Harlaw Academy students visited Elasmogen

Nov 17, 2023 | News

On 13th of November, as part of the Excelerate program, advanced higher biology students from Harlaw Academy visited Elasmogen. The students participated in interactive...

Elasmogen has been announced as a finalist for the Deal & Dealmakers Awards

Jun 20, 2023 | News

Insider.co.uk has announced today the shortlist for the Deal & Dealmakers Awards. Elasmogen is nominated for Early Stage Deal of the Year in partnership with RBC...

Elasmogen team took a part in the regional event hosted by the BIA in collaboration with ONE

May 30, 2023 | News

On 10th of May Elasmogen team took part in the regional event hosted by the BIA in collaboration with opportunity North East. The event took place at the new BioHub....

Dr Jane Dancer named as the new Chair of Elasmogen Ltd

Apr 28, 2023 | News

Elasmogen Ltd has announced the appointment of Jane Dancer as the Chair of the Board. Jane joined Elasmogen as a non-executive director in April 2022 on the back of new...

unique Elasmogen too

Elasmogen and Intract Enter License Agreement for Soteria® and Phloral® Technologies

Sep 16, 2022 | News

Intract Pharma Limited London, UK (“Intract”), and Elasmogen Limited, Aberdeen, Scotland (“Elasmogen”) have announced a global license agreement that gives Elasmogen...

BGF, Scottish National Investment Bank and Scottish Enterprise join forces to invest £8m in Aberdeen biologics company Elasmogen

May 18, 2022 | News

Aberdeen, Scotland, 18 May 2022: Elasmogen – a biopharmaceutical company discovering and developing new therapeutics using its unique soloMERTM platform – has secured...


Shark antibody-like proteins neutralize COVID-19 virus, help prepare for future coronaviruses

Dec 17, 2021 | News

MADISON – Small, unique antibody-like proteins known as VNARs derived from the immune systems of sharks can prevent the virus that causes COVID-19, its variants, and...

Elasmogen Researcher receives prestigious £2m fellowship to help establish him as future UK bioscience leader

Sep 8, 2021 | News

Expertise in drug discovery and the treatment of life-changing inflammatory diseases has been rewarded with prestigious funding via the UKRI’s Future Leaders Fellowship...


Elasmogen announces a panel of novel, potent, anti-Covid-19 therapeutic candidates identified through collaboration with U.S. research partners

Jan 25, 2021 | News

At only one tenth the size of traditional antibodies new VNAR biologics could be used to both treat and protect against SARSCoV-2 infections January 25th 2021:...

Elasmogen announces grants of 2 new VNAR and soloMER patent families

Dec 9, 2020 | News

New grants across multiple territories cover the use of humanised or de-immunised VNARs for therapeutic applications December 9th 2020: Aberdeen, Scotland:  Elasmogen...

elasmogen success too

Elasmogen wins two grants worth £374,000

Jul 8, 2020 | News

New awards for COVID-19 and oncology programs support re-opening of labs in Aberdeen Aberdeen, UK, 8th July 2020:  Aberdeen drug discovery pioneer, Elasmogen Ltd has...

pills too

Intract Pharma and Elasmogen Ltd announce collaboration to discover and develop novel, orally-delivered protein therapeutics

May 5, 2020 | News

Intract Pharma Limited London, UK (“Intract”), and Elasmogen Limited, Aberdeen, Scotland (“Elasmogen”) have announced an agreement to collaborate and develop novel...

Elasmogen Ltd to deploy their soloMER technology platform to develop tools to combat COVID-19

Apr 29, 2020 | News

29th April 2020; Elasmogen Limited, Aberdeen, Scotland (“Elasmogen”) are to collaborate with the University of Aberdeen as a partner on a Scottish Government research...

BBSRC spinouts

Elasmogen featured in Biotechnology and Biological Sciences Research Council Spinout report

Feb 26, 2020 | News

Elasmogen has been featured in BBSRC's report highlighting a few spinout companies that exemplify BBSRC investments in research.

Elasmogen nominated for Innovative Collaboration award with Almac Discovery

Jan 24, 2020 | News

Elasmogen has been nominated for a Life Science Award with Almac Discovery in the Innovative Collaboration category. The finalists in the Innovative Collaboration...

bright idea too

Elasmogen Secures £2 M Funding

Jan 13, 2020 | News

Funding from Deepbridge Capital will support development of next generation biologics January 10th 2020: Aberdeen, Scotland:  Elasmogen Ltd, the biopharmaceutical...

news colour

Elasmogen technology featured in The Times news

Dec 13, 2019 | News

We are delighted that The Times has featured Elasmogen in an article titled 'Ruthless killers? Shark antibodies are latest weapon in fight against cancer'.

caroline barelle too

Elasmogen featured in CONVERGE podcast

Nov 19, 2019 | News

Elasmogen's CEO, Caroline Barelle is featured in Converge's podcast where she discusses her business journey.

Elasmogen CEO Caroline Barelle featured in news outlets as a leader in biotech space

Nov 5, 2019 | News

CIOLook, is currently running a special edition on most prominent women leaders and Elasmogen's CEO, Caroline Barelle has given an interview giving her perspective on...

Caroline Barelle featured in Insights Success

Jul 3, 2019 | News

Elasmogen's CEO Dr Caroline Barelle has been featured in Insight Success special edition Successful Women Making a Difference in Biotech. The article can be read here....

Caroline Barelle

Elasmogen CEO Caroline Barelle named one of top 20 women in leading biotech roles in Europe

May 21, 2019 | News

Biotech media outlet Labiotech.eu which covers the European Biotech industry, has today, 21 May 2019, listed Elasmogen CEO, Dr Caroline Barelle among top 20 women in...

Elasmogen laboratory too

Elasmogen CEO shortlisted for BBSRC Innovator of the Year 2019 award

May 1, 2019 | News

Elasmogen is delighted to announce that shortlisted finalists for the 2019 BBSRC Innovator of the Year award include our CEO, Dr Caroline Barelle. The BBSRC Innovator...

interface too

Almac Discovery and Elasmogen to Share Anti-ROR-1 VNAR Data at American Association of Cancer Annual Meeting

Mar 20, 2019 | News

Craigavon, N.I., UK, 20 Mar 2019 – Almac Discovery, a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of...

Caroline Barelle

Elasmogen CEO Caroline Barelle Interviewed by Life Sciences Scotland for Leadership Insight

Jan 30, 2019 | News

Life Sciences Scotland have interviewed Elasmogen's CEO Caroline Barelle as part of their Insight series. The article can be accessed here.


Elasmogen Licenses NDure™ Half-life Extension Technology to ImmunoForge

Jan 7, 2019 | News

Novel soloMER based albumin binder will be used for two therapeutic fusion proteins™ Aberdeen, Scotland and Seoul, Korea; January 7th 2019:  Elasmogen Ltd, developer of...

BioFit logo

Elasmogen winner of BioFIT 2018 Start-up Slams

Dec 7, 2018 | News

  Lille, 5 December 2018 - Elasmogen wins another prestigious award during the 7th Edition of BioFIT. BioFIT is one of Europe's leading business...


Elasmogen CEO Dr Caroline Barelle wins ‘Academic Entrepreneur of the Year’ award at Entrepreneurial Scotland’s Summit Awards 2018

Nov 26, 2018 | News

Elasmogen’s CEO Dr Caroline Barelle won the Academic Entrepreneur of the Year award at Entrepreneurial Scotland's Summit Awards ceremony which took place on 22nd...

elasmogen and saltire

Summit Awards – Celebrating Scottish Entrepreneurship

Oct 16, 2018 | News

Dr. Caroline Barelle, CEO of Elasmogen, is shortlisted as one of 3 finalists in the Academic to Entrepreneur of the Year category. This category recognises an...

news too

Elasmogen CEO Interviewed by Scottish Business News Network

Aug 20, 2018 | News

Our CEO Caroline Barelle was interviewed by Scottish Business News Network. In her interview, Caroline discusses the journey of starting up Elasmogen and provides an...

lab sample

Almac Discovery, Elasmogen and Innovate UK Collaborate to Develop VNAR Based Oncology Platform

Aug 6, 2018 | News

£2M joint program receives grant to support research into next generation technology Craigavon, N.I., UK, 6 Aug 2018 – Almac Discovery, a biopharmaceutical company...

Dr Caroline Barelle named “Rising Stars: Extraordinary Talent (2017)” at last night’s Scotland’s Life Sciences Dinner & Annual Awards.

May 17, 2018 | News

17th May 2018: Aberdeen, Scotland: Elasmogen Ltd, developer of soloMERTM biologics, today announced that Dr Caroline Barelle was named as the winner in the “Rising...

award-winning Elasmogen too

Elasmogen CEO has been selected as a finalist for the Rising Stars

Jan 29, 2018 | News

Dr. Caroline Barelle (CEO) has been selected as a finalist for the Rising Stars: Extraordinary Talent Award. Some of Scotland’s most dynamic life sciences companies and...

Elasmogen CEO named one of top 14 Female Entrepreneurs in European Biotech by Labiotech.eu

Nov 8, 2017 | News

Elasmogen’s CEO Dr Caroline Barelle has been named in Labiotech.eu’s list of top female entrepreneurs. Read the article here.

elasmogen team at work

Feldan Therapeutics and Elasmogen Announce Research Agreement with Amgen to Develop Intracellular Biologics

May 9, 2017 | News

Combined Feldan Shuttle and Elasmogen soloMER technology will be used to deliver intracellular candidates for two targets   Aberdeen, Scotland and Quebec City,...

a bright idea

Elasmogen receives £1.2 M in grant and equity investment

Mar 16, 2017 | News

Funding from Deepbridge Capital, Innovate UK and Scottish Investment Bank will support development of next generation Ophthalmology biologics   Thursday, 16 March 2017:...

Elasmogen Ltd – shark proteins for drug discovery

Jan 20, 2017 | News,Uncategorised

BBSRC support for research and commercialisation contributed to the creation of award-winning spin-out company Elasmogen by Dr Caroline Barelle and Professor Andrew...

elasmogen centrifuge

Elasmogen Ltd are shortlisted in the OBN Best Start-up Biotech Company Awards 2016

Jul 18, 2016 | News

Aberdeen, UK – [July 2016] OBN announced recently the finalists of its 8th Annual Awards covering Biotech, Medtech, Synthetic Biology and Digital Health. The OBN Awards...

Elasmogen Ltd wins the “Perfect Pitch” at BioTrinity 2016

Mar 27, 2016 | News

Aberdeen, UK – [27th March 2016] As Europe's leading biopartnering and investment conference, BioTrinity brings together investors, pharmaceutical executives and...